Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MRTX

Mirati Therapeutics (MRTX) Stock Price, News & Analysis

Mirati Therapeutics logo

About Mirati Therapeutics Stock (NASDAQ:MRTX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$58.70
$58.70
50-Day Range
$58.70
$59.28
52-Week Range
$27.30
$64.41
Volume
N/A
Average Volume
2.76 million shs
Market Capitalization
$4.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Remove Ads
Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Stock News Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

MRTX Stock Analysis - Frequently Asked Questions

Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($2.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.83) by $0.34. The firm's quarterly revenue was up 203.7% compared to the same quarter last year.

Mirati Therapeutics subsidiaries include these companies: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..

Based on aggregate information from My MarketBeat watchlists, some other companies that Mirati Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH), Humana (HUM) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
11/06/2023
Today
3/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
587
Year Founded
2013

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-740,870,000.00
Net Margins
-1,900.65%
Pretax Margin
-1,899.99%

Debt

Sales & Book Value

Annual Sales
$12.44 million
Price / Cash Flow
N/A
Book Value
$17.31 per share
Price / Book
3.39

Miscellaneous

Free Float
67,861,000
Market Cap
$4.12 billion
Optionable
Optionable
Beta
0.77

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:MRTX) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners